Which statement about transdermal estrogen-containing patches is true?

• A. Hypotension
• B. Hypoglycemia
• C. Osteoporosis
• D. Thromboembolism

Answer: (D)

Transdermal estrogen patches deliver estrogen systemically, so they can promote a procoagulant state and increase the risk of thromboembolism. Although this route avoids first-pass liver metabolism and generally lowers VTE risk compared with oral estrogen, the possibility of血栓 (thromboembolism) remains. That makes thromboembolism a true potential adverse effect of these patches. In contrast, hypotension and hypoglycemia are not typical adverse effects of estrogen patches, and estrogen therapy tends to protect bone density, reducing osteoporosis risk rather than causing it.